AVDL · Avadel Pharmaceuticals PLC - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $77.47M | $68.13M | $52.51M | - | $50.02M | $41.50M | $27.18M | - | $7.01M | $0 |
| Cost of Revenue | - | $6.37M | $5.58M | - | $6.16M | $2.79M | $1.52M | - | $117.0K | $0 |
| Gross Profit | $81.58M | $61.76M | $46.93M | - | $43.87M | $38.72M | $25.66M | - | $6.90M | $1.46M |
| R&D | $27.01M | $4.25M | $4.35M | - | $3.80M | $4.05M | $3.07M | - | $2.85M | $4.22M |
| SG&A | $52.64M | $48.62M | $45.58M | - | $40.39M | $47.41M | $48.62M | - | $39.16M | $46.78M |
| Total Operating Expenses | $79.65M | $52.88M | $49.94M | - | $42.01M | $51.46M | $51.69M | - | $42.01M | $51.00M |
| D&A | - | - | $825.0K | - | - | - | $541.0K | - | - | - |
| Operating Income | $1.94M | $8.88M | ($3.00M) | - | ($327.0K) | ($12.74M) | ($26.04M) | - | ($35.11M) | ($49.54M) |
| Interest Expense | $2.42M | $2.35M | $2.24M | - | $2.82M | $2.72M | $2.59M | - | $1.98M | $2.29M |
| Income Tax | $34.0K | ($3.17M) | $78.0K | - | $88.0K | ($509.0K) | $93.0K | - | $89.0K | $90.0K |
| Net Income | $20.0K | $9.66M | ($4.92M) | - | ($2.63M) | ($13.82M) | ($27.34M) | - | ($36.27M) | ($64.43M) |
| EPS - Basic | $0.00 | $0.10 | ($0.05) | - | ($0.03) | ($0.14) | ($0.30) | - | ($0.41) | ($0.83) |
| EPS - Diluted | $0.00 | $0.10 | ($0.05) | - | ($0.03) | ($0.14) | ($0.30) | - | ($0.41) | ($0.83) |
Balance Sheet
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $79.81M | $63.40M | $56.37M | $51.37M | $28.58M | $28.85M | $35.79M | $31.17M | $51.81M | $49.98M |
| Accounts Receivable | $42.44M | $40.63M | $41.58M | $34.10M | $37.10M | $33.38M | $22.69M | $12.10M | $6.24M | $1.77M |
| Inventory | $23.91M | $23.48M | $20.41M | $20.30M | $16.10M | $13.31M | $11.93M | $10.38M | $5.29M | $0 |
| Accounts Payable | $12.58M | $10.11M | $9.12M | $7.33M | $7.92M | $9.79M | $18.96M | $11.43M | $13.26M | $11.79M |
| Current Assets | $172.23M | $159.10M | $139.26M | $134.21M | $127.26M | $125.78M | $136.03M | $134.20M | $172.25M | $171.23M |
| Total Assets | $199.45M | $187.16M | $167.95M | $164.24M | $158.25M | $157.52M | $167.90M | $164.70M | $203.10M | $200.98M |
| Current Liabilities | $62.49M | $57.06M | $50.93M | $48.83M | $42.78M | $44.61M | $47.81M | $36.85M | $54.05M | $51.50M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | $0 |
| Total Liabilities | $101.22M | $96.45M | $93.88M | $90.39M | $83.59M | $87.23M | $89.52M | $76.96M | $92.95M | $57.78M |
| Stockholders' Equity | $98.22M | $90.71M | $74.07M | $73.85M | $74.66M | $70.29M | $78.38M | $87.74M | $110.15M | $143.19M |
| Retained Earnings | ($789.56M) | ($789.58M) | ($799.25M) | ($794.33M) | ($789.28M) | ($786.66M) | ($772.84M) | ($745.50M) | ($716.71M) | ($680.44M) |
Cash Flow
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($8.23M) | - | - | - | ($29.70M) | - | - | - |
| Investing Cash Flow | - | - | $12.32M | - | - | - | $21.39M | - | - | - |
| Financing Cash Flow | - | - | $690.0K | - | - | - | $13.19M | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 105.3% | 90.7% | 89.4% | - | 87.7% | 93.3% | 94.4% | - | 98.3% | - |
| Operating margin | 2.5% | 13.0% | -5.7% | - | -0.7% | -30.7% | -95.8% | - | -500.6% | - |
| EBITDA margin | - | - | -4.1% | - | - | - | -93.8% | - | - | - |
| Net margin | 0.0% | 14.2% | -9.4% | - | -5.2% | -33.3% | -100.6% | - | -517.2% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | 34.9% | 6.2% | 8.3% | - | 7.6% | 9.8% | 11.3% | - | 40.6% | - |
| SG&A / Revenue | 67.9% | 71.4% | 86.8% | - | 80.7% | 114.2% | 178.9% | - | 558.3% | - |
| Effective tax rate | 63.0% | -48.8% | - | - | - | - | - | - | - | - |
| Return on assets | 0.0% | 5.2% | -2.9% | - | -1.7% | -8.8% | -16.3% | - | -17.9% | -32.1% |
| Return on equity | 0.0% | 10.7% | -6.6% | - | -3.5% | -19.7% | -34.9% | - | -32.9% | -45.0% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | -27.3% |
| Liquidity | ||||||||||
| Current ratio | 2.76 | 2.79 | 2.73 | 2.75 | 2.97 | 2.82 | 2.85 | 3.64 | 3.19 | 3.32 |
| Quick ratio | 2.37 | 2.38 | 2.33 | 2.33 | 2.60 | 2.52 | 2.60 | 3.36 | 3.09 | 3.32 |
| Cash ratio | 1.28 | 1.11 | 1.11 | 1.05 | 0.67 | 0.65 | 0.75 | 0.85 | 0.96 | 0.97 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | 0.00 |
| Debt / Assets | - | - | - | - | - | - | - | - | - | 0.00 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | 0.8x | 3.8x | -1.3x | - | -0.1x | -4.7x | -10.0x | - | -17.8x | -21.6x |
| Equity multiplier | 2.03 | 2.06 | 2.27 | 2.22 | 2.12 | 2.24 | 2.14 | 1.88 | 1.84 | 1.40 |
| Liabilities / Assets | 0.51 | 0.52 | 0.56 | 0.55 | 0.53 | 0.55 | 0.53 | 0.47 | 0.46 | 0.29 |
| Efficiency | ||||||||||
| Asset turnover | 0.39 | 0.36 | 0.31 | - | 0.32 | 0.26 | 0.16 | - | 0.03 | 0.00 |
| Inventory turnover | - | 0.27 | 0.27 | - | 0.38 | 0.21 | 0.13 | - | 0.02 | - |
| Days sales outstanding | 200d | 218d | 289d | - | 271d | 294d | 305d | - | 325d | - |
| Days inventory outstanding | - | 1346d | 1336d | - | 955d | 1743d | 2861d | - | 16491d | - |
| Days payable outstanding | - | 580d | 597d | - | 469d | 1282d | 4547d | - | 41376d | - |
| Cash conversion cycle | - | 984d | 1028d | - | 756d | 754d | -1382d | - | -24561d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 54.9% | 64.2% | 93.2% | - | 613.2% | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | 46.5% | 33.8% | - | 28.6% | 18.8% | 10.6% | - | -29.3% | - |
| Gross profit growth (YoY) | 86.0% | 59.5% | 82.9% | - | 536.1% | 2551.8% | - | - | - | - |
| Operating income growth (YoY) | - | - | 88.5% | - | 99.1% | 74.3% | 8.0% | - | -107.0% | -65.5% |
| Net income growth (YoY) | - | - | 82.0% | - | 92.8% | 78.5% | 11.2% | - | -80.1% | -1.6% |
| EPS growth (YoY) | - | - | 83.3% | - | 92.7% | 83.1% | 37.5% | - | -24.2% | 22.4% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | -27.2% | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 31.6% | 29.1% | -5.5% | -15.8% | -32.2% | -50.9% | - | - | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Business segments
$169.12M totalReportable Segment$169.12M · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing AVADEL PHARMACEUTICALS PLC against the 5 most active filers in the same SIC group.